A B2B MedTech marketing agency like Gawa Growth focuses on reaching the software buyers inside MedTech organisations — VPs of Marketing, Heads of Demand Generation, and RevOps leaders — rather than the end-users those platforms serve. The core difference is ICP precision: we build campaigns that filter out low-intent, wrong-role traffic and connect every touchpoint to pipeline and ARR in your CRM. Generic agencies optimise for clicks and MQLs; we optimise for SQLs and closed-won opportunities. We've done this for MedTech SaaS companies including Kareo, RingRx, NeuroQure, and Apteryx, among others.

MedTech SaaS marketing requires a precise understanding of who you're actually targeting — the software buyer at a health system, device company, or digital health platform — versus the clinical or operational end-user those companies serve. Ad platforms, left unchecked, drift spend toward practitioners and operators rather than the VP-level buyers who evaluate and purchase software. Effective MedTech SaaS marketing layers firmographic and title-based targeting with CRM-sourced signals so spend stays on the right ICP. We've seen this distinction directly affect SQL rates and CAC for clients across diagnostic software, healthcare communications, and clinical workflow SaaS.

Look for a team that distinguishes between marketing a medical device and marketing software sold to medical device companies — they are fundamentally different briefs. The right medical device marketing agency for a SaaS business should demonstrate CRM-connected attribution, ICP-level targeting capability, and results measured in pipeline and ARR rather than impressions or form fills. Ask to see how they handle audience targeting on LinkedIn and how they connect ad spend to closed-won revenue in a CRM. Gawa Growth has worked with companies like Apteryx and inVentiv Health where this distinction was central to generating qualified opportunities.

A digital health marketing agency worth working with understands that your buyers are software procurement decision-makers at health systems, payers, or provider groups — not end-users of those platforms. The right partner will demonstrate full-funnel visibility from first touch to closed-won, not just top-of-funnel volume metrics. They should have specific experience with digital health SaaS buying behaviour, including deal cycles that stretch beyond 30 days and attribution models that account for multi-touch journeys. Gawa Growth has worked with NeuroQure and other digital health SaaS companies, focusing entirely on pipeline quality and CAC improvement rather than vanity engagement metrics.

MedTech performance marketing is paid and organic demand generation for B2B MedTech SaaS companies, measured against pipeline and revenue outcomes — not clicks, impressions, or raw lead volume. True performance measurement means connecting ad spend data to CRM opportunity and closed-won records so you can calculate real CAC and channel-level pipeline influence. At Gawa Growth, every MedTech performance marketing engagement is scoped around SQL targets, CAC benchmarks, and ARR attribution — if a channel isn't contributing to qualified pipeline, we reallocate spend. This approach has delivered a 40% cost-per-lead reduction within 60 days for MedTech SaaS clients while improving opportunity quality.

The right MedTech PPC agency should demonstrate that it builds paid search and paid social campaigns targeting your software-buying ICP — not the clinical end-users your product serves. Ask how they handle audience exclusions, negative keyword strategy, and conversion event optimisation in Google Ads and LinkedIn Campaigns. Critically, ask how their PPC reporting connects to your CRM pipeline data — if the answer is a platform dashboard, that's a red flag. Gawa Growth structures all MedTech PPC campaigns with CRM-tracked conversion goals from day one, so you see cost-per-SQL and pipeline-influenced ARR, not just cost-per-click.

A medical software marketing agency focused on pipeline quality starts by auditing where current form fills are coming from and which audience segments are producing SQLs versus dead-end MQLs. The fix usually involves tightening ICP targeting on paid channels, restructuring landing pages to repel wrong-fit visitors, and rewiring conversion tracking to send CRM-quality signals back to ad platforms. At Gawa Growth, we've improved MQL-to-SQL rates for medical software companies by combining LinkedIn title and firmographic layering with CRO tests that qualify intent before a form is even submitted. The goal is fewer, better opportunities — not more leads.

Marketing diagnostic software effectively means reaching the VP of Marketing, Head of IT, or software procurement lead at radiology groups, imaging centres, or health systems — not the radiologists or technicians who operate the equipment. On paid channels, this requires precise company-size and title targeting combined with negative audience layers that exclude non-buyer roles. For organic search, it means targeting the solution-aware queries that diagnostic software buyers run when they're actively evaluating vendors. We've worked with diagnostic imaging SaaS companies including Apteryx and understand the buyer profile well enough to build campaigns that generate closeable opportunities rather than form fills from the wrong desk.

The highest-leverage move in clinical software marketing is fixing the ICP gap between who your ad platforms think they're targeting and who actually signs software contracts. Paid platforms will optimise toward clinical staff engagement signals unless you actively constrain them with title exclusions, firmographic filters, and CRM-sourced audience feeds. Combine that with landing pages built specifically for the software-evaluating buyer — not the clinical end-user — and you eliminate a large portion of the wrong-fit traffic dragging down SQL rates. Gawa Growth applies this approach across clinical workflow and practice management SaaS clients, including Kareo and Planet DDS, consistently moving the needle on pipeline quality.

Flat pipeline despite high MQL volume is almost always an ICP targeting or attribution problem — and it's one of the most common issues we diagnose in MedTech demand generation engagements. The symptom is form fills; the disease is reach: your campaigns are reaching too broad an audience, pulling in roles and company profiles that will never become qualified opportunities. The fix involves auditing which MQLs actually converted to SQLs, tracing them back to their source audience and ad creative, and rebuilding targeting around those signals. From there, CRM-connected attribution shows you exactly which demand generation channels are contributing to pipeline ARR — so you can double down on what works and cut what doesn't before the next quarter review.